VTYX Key Statistics, Chart & Performance
The current stock price of VTYX is 13.89 USD. In the past month the price increased by 80.62%. In the past year, price increased by 587.62%.
VTYX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to VTYX. When comparing the yearly performance of all stocks, VTYX is one of the better performing stocks in the market, outperforming 99.71% of all stocks.
VTYX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VTYX. No worries on liquidiy or solvency for VTYX as it has an excellent financial health rating, but there are worries on the profitability.
VTYX Financial Highlights
Over the last trailing twelve months VTYX reported a non-GAAP Earnings per Share(EPS) of -1.5. The EPS increased by 36.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.41% | ||
| ROE | -55.71% | ||
| Debt/Equity | 0 |
VTYX Forecast & Estimates
15 analysts have analysed VTYX and the average price target is 13.55 USD. This implies a price decrease of -2.44% is expected in the next year compared to the current price of 13.89.
VTYX Ownership
VTYX Latest News, Press Relases and Analysis
VTYX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.22 | 981.68B | ||
| JNJ | JOHNSON & JOHNSON | 21.07 | 526.82B | ||
| MRK | MERCK & CO. INC. | 12.35 | 270.12B | ||
| PFE | PFIZER INC | 8.02 | 145.84B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.42 | 112.50B | ||
| ZTS | ZOETIS INC | 19.66 | 54.93B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.83B | ||
| VTRS | VIATRIS INC | 5.52 | 14.81B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.55 | 12.19B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.94B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.31B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About VTYX
Company Profile
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 83 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
Company Info
VENTYX BIOSCIENCES INC
12790 El Camino Real, Suite 200
San Diego CALIFORNIA US
Employees: 83
Phone: 17604076511
VENTYX BIOSCIENCES INC / VTYX FAQ
What does VENTYX BIOSCIENCES INC do?
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 83 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
What is the current price of VTYX stock?
The current stock price of VTYX is 13.89 USD. The price increased by 0.22% in the last trading session.
Does VENTYX BIOSCIENCES INC pay dividends?
VTYX does not pay a dividend.
What is the ChartMill technical and fundamental rating of VTYX stock?
VTYX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for VENTYX BIOSCIENCES INC?
VENTYX BIOSCIENCES INC (VTYX) has a market capitalization of 991.19M USD. This makes VTYX a Small Cap stock.
What is the Short Interest ratio of VENTYX BIOSCIENCES INC (VTYX) stock?
The outstanding short interest for VENTYX BIOSCIENCES INC (VTYX) is 8.9% of its float.